Minimal Change Disease
Minimal Change Disease (MCD) is the most common cause of nephrotic syndrome in children (80–90%) and an important cause in adults (10–15% of primary nephrotic syndrome). It is characterized by normal light microscopy, diffuse podocyte foot process effacement on electron microscopy, and absence of immune deposits on immunofluorescence. Despite its name, minimal change refers to light microscopy findings — electron microscopy reveals extensive podocyte injury. MCD typically responds dramatically to corticosteroids, but relapsing disease is common.
Table of Contents
Overview
Minimal Change Disease (MCD) is a glomerulopathy causing nephrotic syndrome via diffuse podocyte foot process effacement without immune deposits. It is the most common cause of nephrotic syndrome in children (80–90% of pediatric nephrotic syndrome under age 10; decreasing proportion in adolescents and adults). In adults, MCD accounts for 10–15% of primary nephrotic syndrome.
The name is a misnomer — light microscopy appears normal, but electron microscopy reveals near-total podocyte foot process effacement across all glomeruli. The disease is immune-mediated, likely involving T-lymphocyte dysfunction producing a circulating permeability factor (not yet definitively identified) that injures podocytes.
Idiopathic MCD responds to corticosteroids in 90% of children and 75–80% of adults, but relapses are frequent. Long-term kidney prognosis is generally excellent if remission is maintained, unlike FSGS which MCD can sometimes be confused with or progress to.
Epidemiology
Peak incidence in children ages 2–8 years (boys > girls 2:1 under age 6; equal over age 6). Annual incidence: 1–3 cases per 100,000 children per year in Western countries; higher in South Asian children. In adults: peak ages 20–30 (idiopathic MCD) and then again over 60 (secondary MCD from nonsteroidal anti-inflammatory drugs (NSAIDs) or lymphoma).
MCD accounts for 90% of childhood nephrotic syndrome under age 6, and approximately 50% in ages 6–12. Overall excellent prognosis with the majority achieving long-term remission. Fewer than 1% progress to end-stage renal disease (ESRD) without a misdiagnosis — most such cases reflect underlying FSGS misread as MCD on an inadequate biopsy sample.
Pathophysiology
The precise mechanism remains unclear, but current evidence supports a T-lymphocyte mediated disorder:
- T-cell dysfunction: CD4+ T helper cell imbalance with Th2 predominance and reduced regulatory T-cells (Tregs); elevated IL-4, IL-13, and IL-21 production. These cytokines may directly injure podocyte slit diaphragms.
- Circulating permeability factor: A soluble factor (possibly IL-13, hemopexin, cardiotrophin-like cytokine, or CD80-related factor) produced by dysregulated T-cells injures podocytes, causing foot process effacement and proteinuria.
- B-cell and antibody role: antibodies against nephrin (anti-nephrin) are now implicated, most often in MCD itself and less often in primary FSGS; rituximab response suggests a B-cell contribution.
- CD80 (B7-1) upregulation on podocytes: Detected in MCD but disputed as a primary driver; CTLA4-Ig (abatacept) trials have been based on this hypothesis.
- Podocyte foot process effacement: Disruption of the slit diaphragm (nephrin-podocin complex) leads to massive loss of selective glomerular permeability, producing heavy proteinuria, albumin loss, hypoalbuminemia, reduced oncotic pressure, and edema.
- Normal light microscopy and absence of immune deposits (no immunoglobulin G (IgG), immunoglobulin A (IgA), immunoglobulin M (IgM), or C3 on immunofluorescence): these findings distinguish MCD from membranous nephropathy, FSGS, and lupus nephritis.
Antibodies against nephrin: a 2024 multicentre study of 539 patients found antibodies against nephrin (a protein of the kidney's filtration slit) in 46 of 105 adults (44%) with MCD and 94 of 182 children (52%) with idiopathic nephrotic syndrome, rising to 69% and 90% in those with active disease who were not yet on immunosuppressive treatment; only 7 of 74 adults (9%) with primary FSGS had them. Antibody levels tracked disease activity, and immunising mice with nephrin produced a nephrotic syndrome resembling MCD (an animal result). These antibodies are the strongest candidate so far for the long-sought circulating factor in some patients.
Clinical Presentation
Nephrotic syndrome is the hallmark presentation:
- Heavy proteinuria (>3.5 g/day in adults; >40 mg/m²/hr in children): the most dramatic finding; frothy urine.
- Hypoalbuminemia (<3.0 g/dL typically; may fall to 1.0–1.5 g/dL in severe MCD): drives edema and ascites.
- Edema: periorbital edema (especially in the morning, often the first sign noticed by parents in children); dependent edema; anasarca in severe cases; ascites; pleural effusions.
- Hyperlipidemia (low-density lipoprotein (LDL) and very-low-density lipoprotein (VLDL) elevation): the liver compensates for albumin loss by increasing apolipoprotein production; lipid-lowering therapy is sometimes used during prolonged nephrotic phases.
- Lipiduria: oval fat bodies, fatty casts (Maltese cross birefringence on polarized light).
- Hypertension: less prominent in MCD than in FSGS; more common in adults.
- Reduced estimated glomerular filtration rate (eGFR) at presentation: uncommon in childhood MCD but occurs in 20–30% of adults with MCD; usually resolves with remission.
- Thromboembolism risk: nephrotic syndrome causes urinary loss of antithrombin III plus protein C and S, creating a hypercoagulable state leading to deep vein thrombosis, pulmonary embolism, and renal vein thrombosis; risk is higher in adults than children.
- Infections: loss of opsonins (factor B, properdin) increases susceptibility to encapsulated organisms; pneumococcal peritonitis is a classic complication in children. The 2023 International Pediatric Nephrology Association (IPNA) recommendations list checking vaccination against pneumococcus, meningococcus, Haemophilus influenzae, hepatitis B, COVID-19, influenza and varicella before immunosuppressants other than prednisone are started.
Diagnosis and Biopsy Findings
In children ages 1–8 with classic nephrotic syndrome, empirical steroid therapy is appropriate without prior biopsy (presumptive MCD; over 90% respond). Biopsy indications in children: age <1 or >10 years, hematuria, hypertension, low C3, family history of renal disease, or steroid resistance at 4–8 weeks.
In adults: biopsy is always required before treatment to distinguish MCD from FSGS, membranous nephropathy, and secondary causes.
Biopsy findings:
- Light microscopy: NORMAL — this is the defining feature. No hypercellularity, no basement membrane thickening, no immune deposits.
- Immunofluorescence: NEGATIVE or trace non-specific deposits. True MCD has no immune deposits.
- Electron microscopy: DIFFUSE podocyte foot process effacement (>75–90% of foot processes obliterated); microvillous transformation of podocytes. This is the diagnostic hallmark.
Lab findings: heavy proteinuria on urine dipstick (3–4+) and 24-hour collection; hypoalbuminemia; hyperlipidemia; normal complement (C3, C4); normal anti-dsDNA, antineutrophil cytoplasmic antibody (ANCA), and anti-GBM. Hematuria is absent or minimal (microscopic hematuria in <25%; gross hematuria is atypical and raises the possibility of FSGS).
Treatment — Initial Corticosteroid Therapy
For idiopathic MCD, prednisone (or prednisolone) is first-line:
- Children: 2 mg/kg/day (max 60 mg/day) for 4 or 6 weeks, then 1.5 mg/kg on alternate days (max 40 mg) for the same 4 or 6 weeks; the 2023 IPNA recommendations advise against a tapering schedule during the alternate-day phase. Complete remission (protein-free urine) in 90% within 4–6 weeks. Earlier response correlates with better prognosis.
- Adults: 1 mg/kg/day (max 80 mg/day) for a minimum of 4 weeks, extending up to 16 weeks before declaring steroid resistance (adults respond more slowly). Alternate-day dosing after initial response. Response rate 75–80% in adults.
- Complete remission defined as: urine protein <4 mg/m²/hr (<0.3 g/day in adults; trace or negative dipstick) for 3 consecutive days.
- Relapse: return of proteinuria after remission — urine dipstick 3+ or more, or urine protein-to-creatinine ratio (UPCR) of 2 mg/mg or more, on 3 consecutive days (2023 IPNA definition). Relapses are re-treated with prednisone at the same starting dose.
Supportive measures:
- Edema management: sodium restriction (2 g/day); loop diuretics (furosemide) for symptomatic edema — overuse can cause volume depletion and acute kidney injury.
- Anticoagulation: low-molecular-weight heparin (LMWH) is used if albumin is <2.0 g/dL with immobility or additional risk factors; warfarin is an option for renal vein thrombosis.
Treatment — Frequent Relapsers and Steroid-Resistant Disease
Frequently relapsing MCD (2 or more relapses in the first 6 months after remission of the first episode, or 3 or more in any 12 months, per the 2023 IPNA definitions) and steroid-dependent MCD (2 consecutive relapses during prednisone therapy or within 14 days of stopping it):
- Cyclophosphamide (CYC): 2–3 mg/kg/day for 8–12 weeks (the 2023 IPNA recommendations: no more than a single course, cumulative dose not above 168 mg/kg). Induces sustained remission in 50–60%; higher relapse rates with shorter courses. Complete blood count (CBC) is checked during treatment (every 14 days in the IPNA table), and the urine for hemorrhagic cystitis. Gonadotoxic — important consideration in children and young adults.
- Mycophenolate mofetil (MMF): 1–2 g/day for 1–2 years. Steroid-sparing in frequently relapsing MCD; relapse is common after stopping. Better tolerated than cyclophosphamide; not gonadotoxic; preferred in children. The mycophenolate label carries a boxed warning: use during pregnancy is associated with increased risks of first-trimester pregnancy loss and birth defects, and the label states that females who can become pregnant must be counselled on pregnancy prevention and planning; the 2023 IPNA recommendations state it is teratogenic in early pregnancy, so effective contraception is used by sexually active female adolescents during treatment.
- Calcineurin inhibitors (CNIs) — cyclosporine or tacrolimus: highly effective for steroid-dependent MCD. Tacrolimus (0.1–0.15 mg/kg/day) is often preferred due to fewer cosmetic side effects than cyclosporine (which causes gingival hyperplasia and hirsutism). Maintains remission in 80–85% while on therapy; frequent relapse after stopping (CNI-dependent disease is common).
- Rituximab (anti-CD20): intravenous (IV) 375 mg/m² for 1–4 doses; effective in steroid-dependent and frequently relapsing MCD. Relapse-free at 2 years approximately 50%; repeat dosing is possible. In a 2015 Italian trial of 30 children aged 1–16 with steroid-dependent disease (15 per group), a single rituximab infusion allowed prednisone to be withdrawn while keeping 3-month proteinuria within the trial's noninferiority margin; all but one child on prednisone alone relapsed within 6 months, against a median of 18 months to relapse with rituximab. Mechanism may involve B-cell depletion interrupting the T-cell dysregulation cascade.
Steroid-resistant MCD — failure to achieve remission after 16 weeks of steroids: re-biopsy to exclude FSGS (sampling error — MCD and FSGS can co-exist, or an early FSGS lesion may have been missed on initial biopsy). It is then usually treated as FSGS (CNI plus steroids).
Secondary Causes of MCD
Secondary causes are part of the evaluation of MCD, especially in adults:
- Nonsteroidal anti-inflammatory drugs (ibuprofen, naproxen, others): the most common drug cause; especially in older adults; interstitial nephritis may co-exist.
- Hodgkin's lymphoma: MCD is a well-recognized paraneoplastic syndrome associated with Hodgkin's lymphoma; treatment of the lymphoma resolves MCD. Adult MCD evaluations commonly include a search for cancer: lymph node examination, complete blood count, and computed tomography (CT) of the chest, abdomen, and pelvis.
- Allergic reactions: bee stings, poison ivy, and certain foods have been implicated in isolated cases.
- Infections: human immunodeficiency virus (HIV) (more commonly causes HIVAN or collapsing FSGS); hepatitis B; syphilis; cytomegalovirus (CMV).
- Other drugs: lithium, gold, mercury, penicillamine, interferon-alpha.
Evaluation includes complete blood count, computed tomography scan, and positron emission tomography (PET) scan if lymphoma is suspected, along with a thorough medication review.
MCD in Adults vs. Children
Adults with MCD differ from children in several important ways:
- Slower steroid response: up to 16 weeks required in adults vs. 4–6 weeks in children.
- Biopsy requirement: always required in adults vs. selective use in children.
- Higher frequency of secondary MCD: nonsteroidal anti-inflammatory drugs and lymphoma are important causes in adults, rare in children.
- More frequent acute kidney injury (AKI) at presentation: 20–30% of adults vs. uncommon in children.
- Higher thromboembolism risk: anticoagulation thresholds are lower in adults.
- CNI-dependence: more common in adults than in children.
In a 2007 series of 95 adults with MCD at one US referral centre, more than a quarter were steroid resistant, 73% relapsed at least once and 28% relapsed frequently; acute kidney failure occurred in 24, who tended to be older and hypertensive, and 4 progressed to kidney failure — these 4 were less likely to have responded to steroids and more likely to show FSGS on repeat biopsy.
FSGS is more common than MCD in adults presenting with nephrotic syndrome, compared to children where MCD predominates — hence biopsy is crucial in adults to avoid treating FSGS as MCD.
Transition to adult nephrology care is an important consideration for pediatric patients who continue to have disease into adulthood.
Prognosis
Children: excellent prognosis. The majority achieve long-term remission after initial or subsequent corticosteroid courses; fewer than 1% develop chronic kidney disease or ESRD. Most children with frequently relapsing disease eventually achieve sustained remission by adolescence.
Adults: also generally good, but with a higher rate of CNI-dependence, more frequent relapses, and occasional progression to chronic kidney disease (CKD) — particularly if the underlying diagnosis is actually FSGS that was misclassified due to sampling error on biopsy.
Factors associated with a more complicated course include: age >10 at onset (adults), frequently relapsing disease, steroid dependence, and requirement for multiple immunosuppressive agents. With careful immunosuppressive management, long-term kidney function preservation is expected in true MCD. The distinction from FSGS remains the most clinically important prognostic determinant.
Key Research Papers
- KDIGO Clinical Practice Guideline for Glomerulonephritis. Kidney Int Suppl. 2012;2(2):139–274. [Superseded by the 2021 and 2025 KDIGO guidelines below.] — Search PubMed
- Kidney Disease: Improving Global Outcomes (KDIGO) Glomerular Diseases Work Group. KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases. Kidney Int. 2021;100(4S):S1–S276. — doi:10.1016/j.kint.2021.05.021 · PubMed PMID: 34556256
- Kidney Disease: Improving Global Outcomes (KDIGO) Nephrotic Syndrome In Children Work Group. KDIGO 2025 Clinical Practice Guideline for the Management of Nephrotic Syndrome in Children. Kidney Int. 2025;107(5S):S241–S289. — doi:10.1016/j.kint.2024.11.007 · PubMed PMID: 40254391
- Vivarelli M, et al. Minimal Change Disease. Clin J Am Soc Nephrol. 2017;12(2):332–345. — Search PubMed · doi:10.2215/CJN.05000516
- Eddy AA, Symons JM. Nephrotic syndrome in childhood. Lancet. 2003;362(9384):629–639. — PubMed PMID: 12944064 · doi:10.1016/S0140-6736(03)14184-0
- Waldman M, et al. Adult minimal change disease: clinical characteristics, treatment, and outcomes. Clin J Am Soc Nephrol. 2007;2(3):445–453. — PubMed PMID: 17699450 · doi:10.2215/CJN.03531006
- Ravani P, Rossi R, Bonanni A, et al. Rituximab in Children with Steroid-Dependent Nephrotic Syndrome: A Multicenter, Open-Label, Noninferiority, Randomized Controlled Trial. J Am Soc Nephrol. 2015;26(9):2259–2266. — doi:10.1681/ASN.2014080799 · PubMed PMID: 25592855
- Iijima K, Sako M, Nozu K, et al. Rituximab for childhood-onset, complicated, frequently relapsing nephrotic syndrome or steroid-dependent nephrotic syndrome: a multicentre, double-blind, randomised, placebo-controlled trial. Lancet. 2014;384(9950):1273–1281. — doi:10.1016/S0140-6736(14)60541-9 · PubMed PMID: 24965823
- Sinha A, Bagga A. Nephrotic syndrome. Indian J Pediatr. 2012;79(8):1045–1055. — Search PubMed · doi:10.1007/s12098-012-0776-y
- Trautmann A, et al. IPNA clinical practice recommendations for the diagnosis and management of children with steroid-sensitive nephrotic syndrome. Pediatr Nephrol. 2023;38(3):877–919. — PubMed PMID: 36269406 · doi:10.1007/s00467-022-05739-3
- Caridi G, Bertelli R, Scolari F, Sanna-Cherchi S, Di Duca M, Ghiggeri GM. Podocin mutations in sporadic focal-segmental glomerulosclerosis occurring in adulthood. Kidney Int. 2003;64(1):365. — doi:10.1046/j.1523-1755.2003.00084.x · PubMed PMID: 12787432
- Hinkes BG, et al. Positional cloning uncovers mutations in PLCE1 responsible for a nephrotic syndrome variant that may be reversible. Nat Genet. 2006;38(12):1397–1405. — Search PubMed · doi:10.1038/ng1918
- Hengel FE, Dehde S, Lassé M, et al. Autoantibodies Targeting Nephrin in Podocytopathies. N Engl J Med. 2024;391(5):422–433. — doi:10.1056/NEJMoa2314471 · PubMed PMID: 38804512
PubMed Topic Searches
- PubMed: Minimal change disease nephrotic syndrome children treatment
- PubMed: Minimal change disease adults corticosteroids outcomes
- PubMed: Minimal change disease rituximab randomized trial
- PubMed: Minimal change disease calcineurin inhibitor tacrolimus
- PubMed: Minimal change disease T-cell pathogenesis cytokines
- PubMed: Podocyte foot process effacement nephrotic syndrome
- PubMed: FSGS minimal change disease differential diagnosis biopsy